Pulmonary Arterial Hypertension Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$10995
Buy Report View Sample

Published: December 13, 2022 Report Code: GDHC254PIDR-ST

Select Item

Pulmonary Arterial Hypertension Market Overview

The Pulmonary Arterial Hypertension (PAH) market size across the 7MM was valued at $4.6 billion in 2019 and is forecast to grow at a CAGR of more than 4% during 2019-2029.

Pulmonary Arterial Hypertension Market Outlook

Pulmonary Arterial Hypertension Market Outlook

To gain more information on the Pulmonary Arterial Hypertension market forecast, download a free report sample

The Pulmonary Arterial Hypertension market research report provides an overview of PAH, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

Market Size (2019) $4.6 billion
CAGR (2019 – 2029) >4%
Key Class of Drugs Endothelin Receptor Antagonists, PDE5 Inhibitors, sGC Stimulator, Prostacyclin Receptor Agonists, BMP 10 Inhibitor, Tyrosine Kinase Inhibitor, and Nitric-Oxide Synthase Endothelial Activator
Leading Players Acceleron, Actelion, Aerovate Therapeutics, Bayer, CMP Pharma, Eli Lilly, Gilead, GlaxoSmithKline, Johnson & Johnson, and Liquidia Technologies

Pulmonary Arterial Hypertension Market Drivers

The major drivers of growth in the PAH market across the 7MM over the forecast period include increased use of combination therapy, launching of the first-in-class drugs sotatercept and imatinib, the launch of United Therapeutics’s pipeline drug ralinepag, and publication of trial data of Merck’s Phase III STELLAR study of sotatercept.

Pulmonary Arterial Hypertension Market Segmentation by Class of Drugs

The key classes of drugs in the PAH market are Endothelin Receptor Antagonists, PDE5 Inhibitors, sGC Stimulator, Prostacyclin Receptor Agonists, BMP 10 Inhibitor, Tyrosine Kinase Inhibitor, and Nitric-Oxide Synthase Endothelial Activator. Endothelin Receptor Antagonists led the US PAH market.

Pulmonary Arterial Hypertension Market Analysis, by Class of Drugs in the US

Pulmonary Arterial Hypertension Market Analysis, by Class of Drugs in the US

For more Pulmonary Arterial Hypertension classes of drugs insights, download a free report sample

Pulmonary Arterial Hypertension Market - Competitive Landscape

Some of the leading players in the Pulmonary Arterial Hypertension market are Acceleron, Actelion, Aerovate Therapeutics, Bayer, CMP Pharma, Eli Lilly, Gilead, GlaxoSmithKline, Johnson & Johnson, and Liquidia Technologies.

Scope

This report provides:

  • Overview of PAH, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

  • Annualized PAH therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments forecast from 2019 to 2029.

  • Key topics including strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the PAH therapeutics market.

  • Comprehensive data assessing emerging trends and mechanisms of action under development for PAH therapy. The most promising candidates in Phase III and IIb development are profiled.

  • Analysis of the current and future market competition in the global PAH therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Develop business strategies by understanding the trends shaping and driving the global PAH therapeutics market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PAH therapeutics market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Acceleron (now a key subsidiary of Merck)
Actelion (now a key subsidiary of Johnson & Johnson)
Aerovate Therapeutics
Bayer
CMP Pharma
Eli Lilly
Gilead
GlaxoSmithKline
Johnson & Johnson
Liquidia Technologies
Merck
Mochida Pharmaceuticals
Northern Therapeutics
Pfizer
Pharmosa Biopharm
United Therapeutics

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Pulmonary Arterial Hypertension: Executive Summary – Updated December 2022, Based on Events Up to November 22, 2022

1.1 PAH market will exhibit moderate growth between 2019 and 2029

1.2 Sotatercept has the potential to become a blockbuster therapy and address an unmet need in PAH

1.3 Reformulation of existing drugs will continue to dominate the PAH pipeline

1.4 What do physicians think?

2 Introduction – Updated December 2022, Based on Events Up to November 22, 2022

2.1 Catalyst

2.2 Related reports

3 Disease Overview – Updated December 2022, Based on Events Up to November 22, 2022

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or staging systems

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 Forecast methodology

4.4.1 Sources used

4.4.2 Forecast assumptions and methods

4.5 Epidemiological forecast for PAH (2019–2029)

4.5.1 Diagnosed incident cases of PAH

4.5.2 Sex-specific diagnosed incident cases of PAH

4.5.3 Age-specific diagnosed incident cases of PAH

4.5.4 Diagnosed prevalent cases of PAH

4.5.5 Sex-specific diagnosed prevalent cases of PAH

4.5.6 Age-specific diagnosed prevalent cases of PAH

4.5.7 Diagnosed prevalent cases of PAH by NYHA functional classes

4.5.8 Diagnosed prevalent cases of PAH by comorbidities

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact

4.6.3 Limitations of the analysis

4.6.4 Strengths of the analysis

5 Disease Management – Updated December 2022, Based on Events Up to November 22, 2022

5.1 Diagnosis and treatment overview

5.2 Clinical practice

5.3 Overview of treatment guidelines

5.4 US

5.5 5EU

5.6 Japan

6 Competitive Assessment – Updated December 2022, Based on Events Up to November 22, 2022

6.1 Overview

7 Unmet Needs and Opportunity Assessment – Updated December 2022, Based on Events Up to November 22, 2022

7.1 Overview

7.2 Curative or stabilizing therapeutics targeting a novel, fourth pathway

7.3 Improved drug administration and side effects

7.4 Improved clinical trial design and slowing disease progression

7.5 Drugs to prevent right heart failure

8 Pipeline Assessment – Updated December 2022, Based on Events Up to November 22, 2022

8.1 Overview

8.2 Promising drugs in clinical development

9 Current and Future Players – Updated December 2022, Based on Events Up to November 22, 2022

9.1 Overview

9.2 Trends in corporate strategy

9.3 United Therapeutics portfolio assessment

9.4 GlaxoSmithKline portfolio assessment

9.5 Johnson & Johnson portfolio assessment

9.6 Merck portfolio assessment

9.7 CMP Pharma portfolio assessment

9.8 Aerovate Therapeutics portfolio assessment

9.9 Tenax Therapeutics portfolio assessment

9.10 Liquidia Technologies portfolio assessment

9.11 Pharmosa Biopharm portfolio assessment

10 Market Outlook – Updated December 2022, based on events up to November 22, 2022

10.1 Global markets

10.1.1 Forecast

10.1.2 Drivers and barriers – global issues

10.2 US

10.2.1 Forecast

10.2.2 Key events

10.2.3 Drivers and barriers

10.3 5EU

10.3.1 Forecast

10.3.2 Key events

10.3.3 Drivers and barriers

10.4 Japan

10.4.1 Forecast

10.4.2 Key events

10.4.3 Drivers and barriers

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.3.1 Forecasting methodology

11.4 Primary research – KOLs interviewed for this report

11.4.1 KOLs

11.5 Primary research – prescriber survey

11.6 About the authors

11.6.1 Analyst

11.6.2 Therapy Area Director

11.6.3 Epidemiologist

11.6.4 Managing Epidemiologist

11.6.5 Vice President of Disease Analysis and Intelligence

11.6.6 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: PAH: key metrics in the 7MM

Table 2: NYHA/WHO functional class (FC)

Table 3: Risk factors and comorbidities for PAH

Table 4: Diagnosed prevalent cases of PAH by comorbidities, N, both sexes, all ages, 2019

Table 5: Treatment guidelines for PAH

Table 6: Country profile – US

Table 7: Country profile – 5EU

Table 8: Country profile – Japan

Table 9: Leading treatments for PAH, 2022

Table 10: United Therapeutics’s disease portfolio assessment, 2022

Table 11: GlaxoSmithKline’s disease portfolio assessment, 2022

Table 12: J&J’s disease portfolio assessment, 2022

Table 13: Merck’s disease portfolio assessment, 2022

Table 14: CMP Pharma’s disease portfolio assessment, 2022

Table 15: Aerovate Therapeutics’s disease portfolio assessment, 2022

Table 16: Tenax Therapeutics’s disease portfolio assessment, 2022

Table 17: Liquidia Technologies’s disease portfolio assessment, 2022

Table 18: Pharmosa Biopharm’s disease portfolio assessment, 2022

Table 19: PAH market – global drivers and barriers, 2019–2029

Table 20: Key events impacting sales for PAH in the US, 2019–2029

Table 21: PAH market – drivers and barriers in the US, 2019–2029

Table 22: Key events impacting sales for PAH in the 5EU, 2019–2029

Table 23: PAH market – drivers and barriers in the 5EU, 2019–2029

Table 24: Key events impacting sales for PAH in Japan, 2019–2029

Table 25: PAH market – global drivers and barriers in Japan, 2019–2029

Table 26: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

Figure 1: Global sales forecast by country for PAH in 2019 and 2029

Figure 2: Analysis of the company portfolio gap in PAH during the forecast period

Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of PAH during the forecast period

Figure 4: Target pathways of the currently marketed drugs for PAH

Figure 5: 7MM, diagnosed incidence of PAH (cases per 100,000 population), both sexes, all ages, 2019

Figure 6: 7MM, diagnosed prevalence of PAH (%), both sexes, all ages, 2019

Figure 7: 7MM, sources used and not used to forecast the diagnosed incident and diagnosed prevalent cases of PAH

Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of PAH by NYHA functional classes

Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of PAH by comorbidities: CTD, PH, CHD, and COPD

Figure 10: 7MM, sources used to forecast the diagnosed prevalent cases of PAH by comorbidities: scleroderma, diabetes

Figure 11: 7MM, diagnosed incident cases of PAH, N, both sexes, all ages, 2019

Figure 12: 7MM, diagnosed incident cases of PAH, N, by sex, all ages, 2019

Figure 13: 7MM, diagnosed incident cases of PAH by age, N, both sexes, 2019

Figure 14: 7MM, diagnosed prevalent cases of PAH, N, both sexes, all ages, 2019

Figure 15: 7MM, diagnosed prevalent cases of PAH, N, by sex, all ages, 2019

Figure 16: 7MM, diagnosed prevalent cases of PAH by age, N, both sexes, 2019

Figure 17: 7MM, diagnosed prevalent cases of PAH by NYHA functional classes, N, both sexes, all ages, 2019

Figure 18: Diagnostic approach to PAH

Figure 19: Unmet needs and opportunities in PAH

Figure 20: Overview of the development pipeline in PAH

Figure 21: Key Phase II/III trials for the promising pipeline agents that GlobalData expects to be licensed for PAH in the 7MM during the forecast period

Figure 22: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of PAH during the forecast period

Figure 23: Analysis of the company portfolio gap in PAH during the forecast period

Figure 24: Global (7MM) sales forecast by country for PAH in 2019 and 2029

Figure 25: Sales forecast by class for PAH in the US in 2019 and 2029

Figure 26: Sales forecast by class for PAH in the 5EU in 2019 and 2029

Figure 27: Sales forecast by class for PAH in the 5EU in 2019 and 2029

Frequently asked questions

Pulmonary Arterial Hypertension Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029 standard reports
Currency USD
$10,995

Can be used by individual purchaser only

Most Popular
$21,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Pulmonary Arterial Hypertension Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Pulmonary Arterial Hypertension reports
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Clinical Trials Scorecard for Investigations in 2023
$695 | March 2024
Pharmaceuticals
New
Borderline Personality Disorder (BPD) Clinical Trial Analysis by Phase, Trial…
$2,500 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Pulmonary Arterial Hypertension Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029 in real time.

  • Access a live Pulmonary Arterial Hypertension Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more